Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice.

Plasmodium falciparum causes 1-2 million deaths annually. Yet current drug therapies are compromised by resistance. We previously described potent and selective triazolopyrimidine-based inhibitors of P. falciparum dihydroorotate dehydrogenase (PfDHODH) that inhibited parasite growth in vitro; however, they showed no activity in vivo. Here we show that lack of efficacy against P. berghei in mice resulted from a combination of poor plasma exposure and reduced potency against P. berghei DHODH. For compounds containing naphthyl (DSM1) or anthracenyl (DSM2), plasma exposure was reduced upon repeated dosing. Phenyl-substituted triazolopyrimidines were synthesized leading to identification of analogs with low predicted metabolism in human liver microsomes and which showed prolonged exposure in mice. Compound 21 (DSM74), containing p-trifluoromethylphenyl, suppressed growth of P. berghei in mice after oral administration. This study provides the first proof of concept that DHODH inhibitors can suppress Plasmodium growth in vivo, validating DHODH as a new target for antimalarial chemotherapy.

[1]  P. Rathod,et al.  Analysis of flavin oxidation and electron-transfer inhibition in Plasmodium falciparum dihydroorotate dehydrogenase. , 2008, Biochemistry.

[2]  P. Rathod,et al.  High-throughput Screening for Potent and Selective Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase* , 2005, Journal of Biological Chemistry.

[3]  Jonathan E. Allen,et al.  Genome sequence of the human malaria parasite Plasmodium falciparum , 2002, Nature.

[4]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[5]  Joanne M. Morrisey,et al.  Resistance mutations reveal the atovaquone‐binding domain of cytochrome b in malaria parasites , 1999, Molecular microbiology.

[6]  J. Marcinkeviciene,et al.  Helicobacter pylori-selective Antibacterials Based on Inhibition of Pyrimidine Biosynthesis* , 2000, The Journal of Biological Chemistry.

[7]  M. Goldenberg.  Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis. , 1999, Clinical therapeutics.

[8]  P. Rathod,et al.  Enzymes of purine and pyrimidine metabolism from the human malaria parasite, Plasmodium falciparum. , 1982, Molecular and biochemical parasitology.

[9]  J. Topliss.  A MANUAL METHOD FOR APPLYING THE HANSCH APPROACH TO DRUG DESIGN , 1977 .

[10]  Nicholas J White,et al.  Antimalarial drug resistance. , 2004, The Journal of clinical investigation.

[11]  J. Clardy,et al.  Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents. , 2000, Structure.

[12]  Timo Heikkilae,et al.  The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. , 2006, Bioorganic & medicinal chemistry letters.

[13]  A. Tatem,et al.  The Limits and Intensity of Plasmodium falciparum Transmission : Implications for Malaria Control and Elimination Worldwide , 2007 .

[14]  P. Rathod,et al.  Potent and Selective Activity of a Combination of Thymidine and 1843U89, a Folate-Based Thymidylate Synthase Inhibitor, against Plasmodium falciparum , 2000, Antimicrobial Agents and Chemotherapy.

[15]  J. Vanallan,et al.  The Structure of Certain Polyazaindenes. VII. 4-Amino-6-methyl-1,3,3a,7-tetrazaindene and Its Derivatives1a , 1961 .

[16]  P. Rathod,et al.  Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum. , 2008, Journal of medicinal chemistry.

[17]  Robert A Copeland,et al.  Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists. , 2005, Methods of biochemical analysis.

[18]  J. Baldwin,et al.  Detergent-dependent Kinetics of Truncated Plasmodium falciparumDihydroorotate Dehydrogenase* , 2007, Journal of Biological Chemistry.

[19]  J. Haynes,et al.  Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique , 1979, Antimicrobial Agents and Chemotherapy.

[20]  A. Boa,et al.  Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase. , 2005, Bioorganic & medicinal chemistry.

[21]  Darrell E Hurt,et al.  Structure of Plasmodium falciparum dihydroorotate dehydrogenase with a bound inhibitor. , 2006, Acta crystallographica. Section D, Biological crystallography.

[22]  J. Topliss,et al.  Utilization of operational schemes for analog synthesis in drug design. , 1972, Journal of medicinal chemistry.

[23]  Pradipsinh K Rathod,et al.  Malarial Dihydroorotate Dehydrogenase , 2002, The Journal of Biological Chemistry.

[24]  Joanne M. Morrisey,et al.  Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum , 2007, Nature.

[25]  E. Johansson,et al.  Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane‐associated N‐terminal domain , 2004, Protein science : a publication of the Protein Society.

[26]  D. Thomas,et al.  Divergent evolution of pyrimidine biosynthesis between anaerobic and aerobic yeasts. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Jiunn H. Lin,et al.  CYP Induction-Mediated Drug Interactions: in Vitro Assessment and Clinical Implications , 2006, Pharmaceutical Research.

[28]  S. Kappe,et al.  Malaria: progress, perils, and prospects for eradication. , 2008, The Journal of clinical investigation.

[29]  J B Houston,et al.  Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.

[30]  M. E. Jones,et al.  Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and regulation of UMP biosynthesis. , 1980, Annual review of biochemistry.

[31]  R. Pink,et al.  Opportunities and Challenges in Antiparasitic Drug Discovery , 2005, Nature Reviews Drug Discovery.

[32]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[33]  W. Gutteridge,et al.  Incorporation of radioactive precursors into DNA and RNA of Plasmodium knowlesi in vitro. , 1970, The Journal of protozoology.

[34]  P. Rosenthal.  Artesunate for the treatment of severe falciparum malaria. , 2008, The New England journal of medicine.

[35]  M. Fry,et al.  Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). , 1992, Biochemical pharmacology.